Literature DB >> 20440512

Characterization of human multicentric osteosarcoma using newly established cells derived from multicentric osteosarcoma.

Y Yamamoto1, N Yamamoto, K Tajima, A Ohno, Y Washimi, D Ishimura, O Washimi, H Yamada.   

Abstract

PURPOSE: Human multicentric osteosarcoma (HMOS) is a rare, aggressive variant of osteosarcoma, and its etiology is not clear. We used newly established HMOS cells, which were derived from primary (HMOS-A) and secondary (HMOS-P) lesions, respectively, to perform a basic study analyzing the cellular biology and gene expression of HMOS.
METHODS: We performed a cell growth assay, an invasion assay, DNA microarray analysis, quantitative real-time RT-PCR (Qrt-PCR), and a telomerase assay and compared the results between HMOS-A, HMOS-P, and human osteosarcoma (HOS) cell lines (MNNG-HOS and Saos-2).
RESULTS: The cell biological analysis revealed that HMOS-A and HMOS-P had similar characteristics to Saos-2, and the invasion assay showed that they had similar characteristics to MNNG-HOS. The DNA microarray study showed that the gene expression profiles of HMOS-A and HMOS-P were similar to that of MNNG-HOS, but the overexpression of MMP-2, MMP-9, and MT1-MMP was observed in HMOS-A and HMOS-P, which was correlated with the invasiveness of the extracellular matrix, and collagen type-4 (COL-4) and VEGF were also detected. HMOS-A and HMOS-P showed low telomerase activity similar to Saos-2, which are known to be telomerase negative, but a similar telomere length and telomerase protein to MNNG-HOS.
CONCLUSIONS: HMOS-A and HMOS-P demonstrated strong invasive ability, and their gene expression profiles correlated with the invasiveness of the extracellular matrix. Their telomerase activity was low, but they did not shown the typical features of alternative lengthening of telomeres (ALT). HMOS-A and HMOS-P are useful models for further study of various biological aspects and therapeutic manipulation of HMOS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440512     DOI: 10.1007/s00432-010-0885-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  35 in total

1.  Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas.

Authors:  C Scheel; K L Schaefer; A Jauch; M Keller; D Wai; C Brinkschmidt; F van Valen; W Boecker; B Dockhorn-Dworniczak; C Poremba
Journal:  Oncogene       Date:  2001-06-28       Impact factor: 9.867

2.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

Review 3.  Alternative lengthening of telomeres in mammalian cells.

Authors:  Jeremy D Henson; Axel A Neumann; Thomas R Yeager; Roger R Reddel
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

4.  Synchronous multifocal osteosarcoma with lymphatic spread in the lung: an autopsy case report.

Authors:  M Hatori; H Ohtani; N Yamada; M Uzuki; S Kokubun
Journal:  Jpn J Clin Oncol       Date:  2001-11       Impact factor: 3.019

5.  Synchronous multicentric osteosarcoma: the case for metastases.

Authors:  R H Daffner; S L Kennedy; K R Fox; J J Crowley; D D Sauser; L A Cooperstein
Journal:  Skeletal Radiol       Date:  1997-10       Impact factor: 2.199

Review 6.  Telomere lengthening in telomerase-negative cells: the ends are coming together.

Authors:  Christina Scheel; Christopher Poremba
Journal:  Virchows Arch       Date:  2002-04-09       Impact factor: 4.064

7.  Metastatic osteosarcoma gene expression differs in vitro and in vivo.

Authors:  Jennifer W Lisle; Joseph Y Choi; Jason A Horton; Matthew J Allen; Timothy A Damron
Journal:  Clin Orthop Relat Res       Date:  2008-05-31       Impact factor: 4.176

8.  CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis.

Authors:  Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Shuichi Matsuda; Kazuhiro Tanaka; Ryohei Yokoyama; Yukihide Iwamoto; Masazumi Tsuneyoshi
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

Review 9.  Tumor metastasis to bone.

Authors:  Mandeep S Virk; Jay R Lieberman
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 10.  Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development.

Authors:  C V Hojilla; F F Mohammed; R Khokha
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  5 in total

Review 1.  Osteosarcoma of the jaws: a review of literature and a case report on synchronous multicentric osteosarcomas.

Authors:  Peter M Nthumba
Journal:  World J Surg Oncol       Date:  2012-11-12       Impact factor: 2.754

2.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

3.  Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors.

Authors:  Tomas Goncalves; Georgia Zoumpoulidou; Carlos Alvarez-Mendoza; Caterina Mancusi; Laura C Collopy; Sandra J Strauss; Sibylle Mittnacht; Kazunori Tomita
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-07

Review 4.  ALT Positivity in Human Cancers: Prevalence and Clinical Insights.

Authors:  Danny MacKenzie; Andrea K Watters; Julie T To; Melody W Young; Jonathan Muratori; Marni H Wilkoff; Rita G Abraham; Maria M Plummer; Dong Zhang
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

5.  Overexpression of KIAA1199, a novel strong hyaluronidase, is a poor prognostic factor in patients with osteosarcoma.

Authors:  Kan Ito; Yoshihiro Nishida; Kunihiro Ikuta; Hiroshi Urakawa; Hiroshi Koike; Tomohisa Sakai; Jiarui Zhang; Yoshie Shimoyama; Shiro Imagama
Journal:  J Orthop Surg Res       Date:  2021-07-07       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.